AQST vs SPRY
AQST: Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film platforms. SPRY: Biopharmaceutical company commercializing neffy, the only FDA-approved needle-free intranasal epinephrine for emergency anaphylaxis treatment.
Side-by-side fundamentals
| Metric | AQST | SPRY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.94 | $6.06 | |
| Market cap as of 2026-07-23 | $496M | $602M | |
| PEG as of 2026-07-23 | -2.03 | -0.00 | AQST lower |
| Net margin as of 2026-07-23 | -137.1% | -200.0% | AQST higher |
| Gross margin as of 2026-07-23 | +63.5% | +74.1% | SPRY higher |
| Operating margin as of 2026-07-23 | -111.2% | -204.5% | AQST higher |
| ROE as of 2026-07-23 | -21.8% | -153.6% | AQST higher |
| ROA as of 2026-07-23 | -49.3% | -60.9% | AQST higher |
| Debt / equity as of 2026-07-23 | 4.68 | 1.57 | SPRY lower |
| Revenue growth (YoY) as of 2026-07-23 | -7.3% | +1.9% | SPRY higher |
| Revenue CAGR (3y) SEC XBRL | -2.2% | +300.1% | SPRY higher |
| Beta as of 2026-07-23 | 1.45 | 1.02 | |
| 1-year return as of 2026-07-22 close | -4.5% | -64.4% | AQST higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.